38 innovations from Bar-Ilan University, available for licensing, co-investment, or spin-out through BIRAD.
Mandel Yossi
The invention relates to a stimuli-responsive carrier system that enables controlled, transient, and reversible release of therapeutic and other functional substances. The system is based on a polymeric matrix crosslinked by redox-active metal ions, whose mechanical properties and diffusivity can be reversibly modulated by externally applied stimuli, such as ascorbic acid (Vitamin C) or visible light irradiation. Upon application of the stimulus, the matrix transiently softens and becomes permeable, allowing controlled release of incorporated cargos. Removal of the stimulus results in autonomous recovery of the matrix to its original, mechanically robust state, halting further release. The dissipative mechanism enables repeated on-demand release cycles from a single carrier depot without permanent degradation. The invention has broad applicability, including medical, ocular, industrial, and environmental uses. The invention is a collaborative effort of HUJI (Prof. Itamar Willner) and BIU (Prof. Yossi Mandel). BIU will share parts of the invention that are related solely to ocular use of the application.
Barda-Saad Mira
The focus of this patent application is the development of a novel therapeutic approach for controlling and improving NK cell killing of cancer cells or viruses in vivo by suppressing the key negative regulators of NK cell cytotoxicity. Natural-killer (NK) cells represent a powerful weapon of immune defense against viral infections and tumor growth, via cytotoxicity of target cells. Specifically, NK cells are particularly efficient in removing metastatic cells and tumor grafts. We recently revealed that NK cell response is inhibited by two main mechanisms: (1) dephosphorylation of signaling molecule by the protein tyrosine phosphatase SHP-1, and (2) ubiquitylation mediated degradation of signaling molecule by the E3 ubiquitin ligases c-Cbl and Cbl-b. These molecular events block NK cell activation; however, their suppression increases NK cell cytotoxicity of cancer cells. NK cell-based immunotherapies represent a promising strategy to combat cancer, yet, no clinical trial has demonstrated a significant benefit in malignancies. Our novel approach for improving NK cell killing of cancer cells is composed of an in vivo NK-targeted drug-delivery system that strike the molecular mechanisms that inhibits NK cell activation, i.e. SHP-1 and the Cbls, using specific siRNA. To specifically target the NK cells, the siRNA will be coupled to nanoparticles coated with specific antibodies to NK cells.
Byk Gerardo
The invention describes the synthesis of new nanoparticles with monodispersed sizes from 20 to 500 nm. The nanoparticles complex nucleic acids and is able to transfer genes into mammalian cells to express a foreign protein. The singularity of the nanoparticles is that they are highly biocompatible. The complexes can be incubated with cells for undetermined time without toxicity. The expression of the foreign protein start at low level after 48h but arrives to high level after 1 week with no toxicity. The transfected cells can be passed several times without loss of protein expression, indicating a controlled release of the nucleic acids and their expression. The invention includes the use of DNA or RNA. Finaly, in vivo experiments demonstrated that the gene can be administered for example SC or IM and the protein expression can be detected after 1 month.
Yadid Gal Moshe
Synthetic delta receptor peptide agonists as a new treatment for cocaine addiction and pain.
Moran Dvela Levitt
TMED proteins are implicated as oncogenic proteins in brain tumors and a variety types of additional tumors. We found that inhibition and downregulation of members of the TMED family, pharmacologically through treatment with the preclinical drug BRD4780, or genetically through siRNA or KO exert anti-tumor effect. This includes decrease in growth, migration and aggressiveness and targeting of cancer stem cell self-renewal. Additionally, TMED targeting increases treatment sensitivity to chemotherapy in different types of brain tumors including glioblastoma or pediatric brain tumors such as Diffuse Intrinsic Pontine Glioma (DIPG).
Yadid Gal Moshe
New psychodelic - like substance for novel treatment for addiction
Gruzman Aric-lev
Novel TRAM-Derived Decoy Peptides and Peptidomimetics as Cardioprotective Therapeutic Agents
Levanon Erez
system to design guides for selected gene targeting by the ADAR enzyme
Gruzman Aric-lev
Inhibitors of leucocyte rolling and recruiting as an anti-inflammatory novel drug candidates
Nudelman Abraham
Indoline derivatives possessing antioxidant and anti-inflammatory properties for the treatment of hronic inflammatory diseases
Lellouche Jean-Paul
Innovative Nanoscale Formulations of siRNA/microRNA Species for Effective Gene Silencing Comprising Methods of Preparation of Corresponding Magnetic Iron Oxide-Based Nanocarrier Particles
Ruthstein Sharon
64Cu based radiotracer for hypoxia induction for PET/SPECT imaging
